The New York Genome Center (NYGC) is an independent, nonprofit academic research institution that serves as a multi-institutional hub for genomic research. Leveraging our strengths in whole-genome sequencing and genomic analysis, our mission is the advancement of genomic science and its application to drive novel biomedical discoveries. NYGC’s areas of focus include the development of computational and experimental genomic methods and disease-focused research to better understand the genetic basis of cancer, neurodegenerative disease, and neuropsychiatric disease. In 2020, the NYGC also has directed its expertise to COVID-19 research.
We are committed to prioritizing diversity, equity, and inclusion, which is fundamental to promoting greater collaboration, innovation, and discovery. Learn more about NYGC’s Commitment to Diversity, Equity, and Inclusion.
The five-year, $8.5 million award will support the research project entitled "The physical biology of neurodegeneration in sporadic Amyotrophic Lateral Sclerosis/Frontotemporal dementia." Dr. Phatnani, who holds a joint appointment as Assistant Professor of Neurological Sciences in the Department of Neurology, Division of Neuromuscular Medicine, at Columbia University, will serve as lead principal investigator working in collaboration with researchers at Columbia University, New York University, and The University of Edinburgh.
A team led by researchers at Weill Cornell Medicine, Harvard Medical School and the New York Genome Center has profiled in unprecedented detail thousands of individual cells sampled from patients’ brain tumors. The findings, along with the methods developed to obtain those findings, represent a significant advance in cancer research, and ultimately may lead to better ways of detecting, monitoring and treating cancers.
VIDEO: Michael Zody, PhD, Discusses Collaborative SARS-CoV-2 Viral Surveillance Initiatives at the NYGC
NYGC’s Scientific Director of Computational Biology details the sequencing/data sharing activities of the COVID-19 Genomics Research Network (CGRN) and shares findings of two CGRN studies, one focused on immunocompromised COVID patients and another on assessing post-vaccination infection breakthroughs.
2021 NYGC ALS Consortium Meeting: Celebrating Achievements, Ongoing Collaborations to Advance ALS Research
Over 100 clinicians and researchers from the Consortium’s member institutions dialed into the virtual event, sharing presentations on their latest ALS genomics research. The occasion was also an opportunity to mark and celebrate over five years of progress of the Consortium, which has fostered ALS data sharing on an unparalleled and unprecedented scale.
Sanjana Lab of NYGC/NYU Extends RNA-Targeting CRISPR-Cas13 Genomics Tools to Model Organisms and Viruses Including SARS-CoV-2
Tom Maniatis, PhD, NYGC Evnin Family Scientific Director & CEO, Named to City & State’s First “Life Sciences Power 50” List
NYGC board members, scientists from NYGC member institutions, and NYGC collaborative partners and supporters are also among the honorees recognized as forward-thinking leaders driving the life sciences sector’s growth in New York.
01 / 02
Nature Biotechnology. 2021 Sept. 9.
Communications Biology. 2021 Sept. 1.